产碳青霉烯酶肺炎克雷伯菌在接受头孢他啶/阿维巴坦治疗后体内出现头孢地尔和头孢他啶/阿维巴坦交叉耐药性。
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.
机构信息
Division of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Clinical Infectious Diseases Unit IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
出版信息
Diagn Microbiol Infect Dis. 2024 Sep;110(1):116372. doi: 10.1016/j.diagmicrobio.2024.116372. Epub 2024 May 21.
We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop. Taken together, our results indicate that prolonged exposure to ceftazidime/avibactam can confer cross-resistance to ceftazidime/avibactam and cefiderocol.
我们描述了产 KPC 肺炎克雷伯菌感染患者中头孢他啶/阿维巴坦和头孢地尔肟交叉耐药性的出现。所有具有头孢他啶/阿维巴坦和头孢地尔肟交叉耐药性的菌株在 KPC Ω-环上均显示出点突变。综上所述，我们的结果表明，长时间接触头孢他啶/阿维巴坦可导致对头孢他啶/阿维巴坦和头孢地尔肟的交叉耐药性。
Zotero 插件